The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In treatment-experienced patients, findings showed Xemfiby exposure was similar between weekly and biweekly dosing. The Food and Drug Administration (FDA) has expanded the approval of Xembify ® ...
Please provide your email address to receive an email when new articles are posted on . The company expects Xembify’s expanded use to be available in the U.S. by the end of September. The expanded ...
BARCELONA, Spain, July 29, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that the United ...
Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols' subcutaneous Ig) every two weeks, compared with weekly, in patients ...
Grifols (GRFS) is accelerating adoption of XEMBIFY ® as part of its broader immunoglobulin business strategy focused on treating immunodeficiency disorders, which represent up to 55% of the total ...
Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market and whose growth is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results